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Background: Non-alcoholic fatty liver disease (NAFLD) is one of the most common forms
of chronic liver diseases closely associated with obesity and insulin resistance; deficient
growth hormone (GH) action in liver has been implicated as a mechanism. Here, we
investigated the evolution of NAFLD in aged mice with liver-specific GHR deletion.
Methods: We examined glucose tolerance, insulin responsiveness, and lipid profiles in
aged male mice (44–50 weeks) with GHRLD. We performed proteomics analysis, pathway-
based Superarray assay, as well as quantitative RT-PCR to gain molecular insight into
the mechanism(s) of GHR-deficiency-mediated NAFLD. In addition, we examined the
pathological changes of livers of aged GHRLD male mice.
Results: The biochemical profile was consistent with that of the metabolic syndrome:
abnormal glucose tolerance, impaired insulin secretion, and hyperlipidemia. RT-qPCR analy-
sis of key markers of inflammation revealed a three- to fivefold increase inTNFα and CCL3,
confirming the presence of inflammation. Expression of fibrotic markers (e.g., Col1A2 and
Col3A1) was significantly increased, together with a two- to threefold increase in TGFβ
transcripts. Proteomics analyses showed a marked decrease of Mup1 and Selenbp2. In
addition, pathway-analysis showed that the expression of cell cycle and growth relevant
genes (i.e., Ccnd1, Socs2, Socs3, and Egfr) were markedly affected in GHRLD liver. Micro-
scopic analyses (H&E) of GHRLD livers revealed the presence of hepatic adenomas of
different stages of malignancy.
Conclusion: Abrogation of GH signaling in male liver leads to metabolic syndrome, hepatic
steatosis, increased inflammation and fibrosis, and development of hepatic tumor. Since
obesity, a common precursor of NAFLD, is a state of deficient GH secretion and action,
the GHRLD model could be used to unravel the contribution of compromised hepatic
GH signaling in these pathological processes, and help to identify potential targets for
intervention.
Keywords: growth hormone receptor, hepatic steatosis, hepatocellular adenoma, NAFLD
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the most common
type of liver disease that affects 20–40% of the adult population
in developed countries. It describes a spectrum of conditions of
hepatic fat accumulation that is not caused by excessive alcohol
consumption, but rather closely associated with metabolic disor-
ders (1). While the underlying mechanisms of NAFLD are not fully
understood at present, factors relevant to metabolic syndromes,
such as insulin resistance, obesity, hyperlipidemia, and hyper-
glycemia, all contribute to excessive fat deposition in the liver (2–
4). Left untreated, NAFLD can progress to NASH (non-alcoholic
steatohepatitis), where lipid accumulation in hepatocytes leads to
cellular damage and chronic inflammation, resulting in liver fibro-
sis and cirrhosis, as well as the development of hepatic carcinomas
and other forms of liver tumors (5, 6).
Growth hormone (GH), produced and secreted by the pituitary
gland, is a pleiotropic hormone that functions as a key regulator of
postnatal body growth and development. It controls a broad range
of anabolic processes, such as cellular proliferation, differentiation,
nitrogen retention, and bone elongation. In addition, evidence has
accumulated for a role of GH in maintaining metabolic home-
ostasis in adults. Mice deficient in its cognate receptor, the growth
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hormone receptor (GHR), have increased adiposity while exhibit-
ing improved insulin sensitivity (7). Abrogating GHR specifically
in β-cells results in impaired glucose stimulated insulin secretion
and decreased compensatory proliferation in response to high fat
diet (8). While the role of GH signaling in muscle cells remains
under debate, both insulin sensitivity and adiposity are affected
in GHR muscle-specific knockout mice (9, 10). Deletion of GHR
in fat cells results in increased body fat accumulation, with no
detectable influence on glucose metabolism (11, 12).
To study the function of GH signaling in liver, we previ-
ously generated mice with GHR liver-specific deletion (GHRLD)
(13). GHRLD mice develop hyperglycemia, hyperinsulinemia, and
marked insulin resistance as a result of high circulating GH act-
ing on tissues such as muscle and fat in which GH signaling
has remained intact (13). Notably, GHRLD mice develop severe
hepatic steatosis as early as 6–8 weeks of life while on a normal
diet, largely due to increased triglyceride (TG) synthesis together
with compromised export of TG and elevated supply of free fatty
acids (13, 14). These findings have been confirmed in a separate
independent study (15). Consistent with these findings, abroga-
tion of signal transducer and activator of transcription 5 (STAT5)
(16, 17), or Janus kinase 2 (JAK2) (14), the downstream signaling
cascade of GH mediated through GHR in liver, results in hepatic
steatosis and enhanced cell proliferation. Thus, GH and its down-
stream signaling, mediated through GHR, are essential for normal
hepatic lipid metabolism and homeostasis.
In the present study, we investigated NAFLD progression in
aged GHRLD mice (44–50 weeks) and found that a significant
percentage developed symptoms of NASH, with increased mark-
ers of inflammation and fibrosis. Moreover, a subset of GHRLD
mice ultimately developed hepatic adenomas spontaneously, while
on a normal chow diet.
MATERIALS AND METHODS
MICE
C57BL/6 mice were purchased from the Jackson Laboratory (Bar
Harbor, ME, USA). GHR liver-specific deletion (B6.GHRLD) mice
have been described previously (13). Unless specified otherwise,
only male GHRLD mice and age- and gender-matched controls
were used. All mice were housed in a specific pathogen-free animal
facility at the Rangos Research Center, Children’s Hospital of Pitts-
burgh. All animal experiments were carried out under protocols
approved by the Institutional Animal Care and Usage Committee
of the University of Pittsburgh.
RT-qPCR ANALYSIS
The total RNA of a liver sample was isolated using RNeasy
mini kit, according to the manufacturer’s protocol (#74104,
Qiagen, Valencia, CA, USA). Following DNase I treatment
(Ambion, Life Technologies, Grand Island, NY, USA), RNA sam-
ples were reverse-transcribed into cDNAs with Superscript III
cDNA kit (#18080-051, Invitrogen). qPCR analyses of gene
expression in cDNA samples were performed with the Light-
Cycler FastStart DNA Master SYBR Green I kit, and analyzed
with the LightCycler 2 software (#03003230001, Roche Applied
Science), as previously described (18). The following primers
were used: Hprt (F 5′-GGATACAGGCCAGACTTTGTTGGA-3′,
R 5′-CAACAGGACTCCTCGTATTTG CAG-3′), Col1A2 (F 5′-
CCAGAGTGGAACAGCGATTAC-3′, R 5′-GATGCAGGTTTCAC
CA GTAGAG-3′), Col3A1 (F 5′-CCTGGTGGAAAGGGTGAAAT-
3′, R 5′-CGTGTTCCGGGTATAC CATTAG, Col6A1 (F 5′-
ACGTGTTTGACTTCATCCCAGGCT-3′, R 5′-AGATCTGGGCG
GTGACATTCTTCA-3′), TGFβ1 (F 5′-CGAAGCGGACTACTATG
CT AAA-3′, R 5′-TCCCGAATGTCTGACGTATTG-3′), CCL3 (F
5′-GAAGATTCCACGCCAATTC ATC-3′,R 5′-GATCTGCCGGTT
TCTCTTAGTC-3′), IL-1a (F 5′-GAAGAAGAGACGGCTGAGT
TT-3′, R 5′-TCACTCTGGTAGGTGTAAGGT-3′), IL-1b (F 5′-
CCACCTCAATGGACAGAATAT CA-3′, R 5′-CCCAAGGCCACA
GGTATTT-3′), TNFα (F 5′-TTGCTCTGTGAAGGGAATGG-3′,
R 5′-GGCTCTGAGGAGTAGACAATAAAG-3′), Cse3a (F 5′-
TTCGGTAACTCTGCTGGAGGC ATT-3′,R 5′-ACTCTGCGATAT
GGCTCTGTGGAA-3′), Selenbp2 (F 5′-AAGGGCTGGATGTTG
CCAGAAATG, R 5′-TGCAGCCAGTTGCTGAAGTAAAGG-3′),
Mup1 (F 5′-ATGAAGATGCT GCTGCTGCTG-3′, R 5′-ATTCTTC
ATTCTCGGGCCTG-3′). Ccnd1 (F 5′-CAGAGGCGGATGAGAAC
AAG-3′, R 5′-GAGGGTGGGTTGGAAATGAA-3′).
Superarray analysis was performed with ABI 7900HT real-
time PCR system (Applied Biosystems). Total RNA samples
were isolated from 8 to 10 weeks old male GHRLD and con-
trols, and reverse-transcribed as described above. cDNA sam-
ples were subjected to assay with mouse JAK/STAT Signal-
ing Pathway RT2 Profiler™ PCR Array kit (Qiagen), follow-
ing the manufacturer’s instructions. The Superarray experiment
was performed in triplicate. Relative levels of gene expression
were determined by the data analyzer template provided by
Qiagen (http://www.qiagen.com/us/products/genesandpathways/
data-analysis-center-overview-page).
For RT-PCR analysis of Ccnd1 mRNA expression, 2µg of total
RNA isolated from 44 to 50 weeks old male GHRLD (n= 4) and
control mice (n= 4) were reversely transcribed as above. cDNA
samples transcribed from 10 ng of total RNA were subjected to
PCR amplification, with primers specific to Ccnd1 (30 cycles) and
Hprt (25 cycles), and separated by agarose gel electrophoresis.
BLOOD GLUCOSE MEASUREMENT AND INTRAPERITONEAL GLUCOSE
TOLERANCE TEST
Blood glucose levels were measured with the Ascensia Con-
tour blood glucose monitoring system (Bayer HealthCare LLC,
Mishawaka, IN, USA). IPGTT was performed as previously
described (19). Briefly, mice were fasted overnight (~16 h) and
injected intra-peritoneally with a bolus of 2 g of d-glucose (Sigma-
Aldrich, St. Louis, MI, USA) per kilogram of body weight. Blood
was sampled from a small nick of the tail-vein at 0, 15, 30, 60, 90,
and 120 min after glucose injection.
LIVER HISTOLOGY
Liver samples were preserved in 10% phosphate buffered for-
malin (Fisher Scientific). Fixed liver specimens were embed-
ded in paraffin, sectioned with microtome (Leica Microsystems).
Five micron sections were stained with hematoxylin and eosin
(H&E), and examined by a pathologist specialized in liver tumors
at Children’s Hospital of Pittsburgh. Tumor types were scored
according to the WHO international classification of rodent
tumors (20).
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LIQUID CHROMATOGRAPHY FRACTIONATION OF LIPOPROTEINS
Plasma samples were harvested and pooled from 16 to 20 weeks
old male GHRLD mice (n= 6) and age- and gender-matched con-
trol littermates (n= 6). Two hundred fifty microliters of plasma
samples were loaded to Superose 6 10/300GL high-performance
Tricorn columns (GE Healthcare Life Sciences) using a fast pro-
tein liquid chromatography system (Amersham Biosciences), and
eluted with PBS at a constant flow rate of 0.5 ml/min. TG and
cholesterol concentrations in each fraction (500µl) were assayed
with Thermo Infinity TG and Thermo Infinity cholesterol kits,
respectively (Thermo Scientific).
WESTERN BLOT AND ELISA
Protein extracts were isolated from homogenized liver tis-
sues of 16–20 weeks male GHRLD mice and littermate con-
trols, using T-PER Tissue Protein Extraction Reagent (#78510,
Pierce Biotechnology, Rockford, IL, USA), following manu-
facturer’s suggested protocol. Twenty micrograms of protein
lysates were separated with electrophoresis, transferred to PVDF
membrane, and probed with primary antibodies against Ces3
(1:1000, #AF5985, R&D Systems, Minneapolis, MN, USA) and
Selenbp2 (1:1000, #orb4825, Biorbyt LLC, San Francisco, CA,
USA). The membranes were subsequently blotted with HRP-
conjugated secondary antibodies, and incubated with ECL plus
chemiluminescent substrates (Pierce Biotechnologies, Thermo
Scientific). The intensity of protein bands was quantified
by densitometry using the ImageJ software (NIH, Bethesda,
MD, USA).
Levels of Mup1 expression in livers were analyzed with the
Mouse Major Urinary Protein-1 Immunoassay Kit (#orb54814,
Biorbyt LLC, San Francisco, CA, USA), following manufacturer’s
protocol. To ensure that the Mup1 concentrations in the samples
were within the detection range of the assay kit, liver lysates of
controls and GHRLD mice were diluted 2000- and 500-fold in
1× assay buffer, respectively. The results were normalized to the
concentration of proteins in the lysates, measured by BCA assay
kit (#23225, Pierce Biotechnologies, Thermo Scientific), following
manufacturer’s protocols.
PROTEOMICS ANALYSIS
Proteomics analyses of liver samples were described previously
(21). Briefly, liver tissues (40 mg) were homogenized in 800µl
of Mammalian Protein Extraction Reagent (M-PER) buffer sup-
plemented with protease inhibitor cocktail (Pierce Biotechnol-
ogy, Rockford, IL, USA). Albumin was removed from protein
extracts with Aurum serum protein mini kit (Bio-Rad Labora-
tory, Inc.). Three hundred micrograms of liver protein samples
of GHRLD and control mice were precipitated by 2-D Clean-
Up Kit (GE Healthcare, Piscataway, NJ, USA) and dissolved in
90µl lysis buffer (7 mol/l urea, 2 mol/l thiourea, 4% w/v CHAPS,
1% v/v Triton X-100, 10 mmol/l dithiothreitol). Thirty micro-
liters of each sample was combined to create a mixed standard
sample for Cy2 labeling. The remaining aliquots of the con-
trol and GHRLD samples were incubated with 1 nmol Cy3 or
1 nmol Cy5, respectively. After quenching, the samples were mixed
with immobilized pH gradient (IPG) buffer, and applied to an
IPG strip (pH 4–7, 24 cm) and incubated for 20 h using low
voltage (30 V) in an Ettan IPGphor II IEF system (GE Healthcare).
After isoelectric focusing (300 V for 30 min, 500 V for 30 min,
1000 V for 1 h, and 8000 V for 10 h), the strip was equilibrated
with 10 ml of 2.5% w/v iodoacetamide containing equilibra-
tion buffer [2% w/v sodium dodecyl sulfate (SDS), 50 mmol/l
Tris–HCl pH 8.8, 6 mol/l urea, 30% glycerol, and 0.001% bro-
mophenol blue]. Second-dimension SDS–polyacrylamide gel elec-
trophoresis was performed by transferring the IPG strip to a
12.5% single-percentage gel and electrophoresing for about 18 h
at 10°C.
Two-dimensional (2-D) gels were scanned using a Typhoon
9400 variable mode imager (GE Healthcare). Imager settings used
blue-excited fluorescence (488 nm) for Cy2, green-excited fluores-
cence (532 nm) for Cy3, and red-excited fluorescence (633 nm)
for Cy5. Data analysis was performed using DeCyder differen-
tial analysis software, version 5.02 (GE Healthcare). Gel images
were processed for spot detection and determination of the rela-
tive protein abundance based on fluorescence intensity, defined as
spot volume. Change of expression of a specific protein was deter-
mined by dividing the spot volume in the GHRLD sample by that
of the control sample. Protein spots were selected as up-regulated
or down-regulated among those exceeding a twofold difference in
fluorescence intensity. Differentially expressed proteins were man-
ually spot-picked from Coomassie Blue G-250 (Bio-Rad, Hercules,
CA, USA) stained gels.
Dried peptides from in-gel digestion were dissolved in 3µl of
50% acetonitrile and 0.3% TFA, and mixed with 3µl of freshly pre-
pared matrix solution (10 mg/ml α-cyano-4-hydroxy-cinnamic
acid in 50% acetonitrile, 0.3% TFA). The mixture, 0.6µl, was
spotted onto a MALDI plate (Applied Biosystems). The 4700 Pro-
teomics Analyzer MALDI-TOF/TOF (Applied Biosystems) was
used to identify proteins from the trypsin digest. Analysis of
samples used reflector positive ion mode acquisition and pro-
cessing method to collect peptide spectra in the mass range of
800–4000 days. The 10 highest-intensity peptides were selected for
tandem mass spectrometry analysis using tandem mass spectrom-
etry mode acquisition with the 1-kV positive ion and processing
method. Data processing was performed with GPS Explorer Work-
station (Applied Biosystems) and MASCOT database analysis of
mammalian proteins.
STATISTICAL ANALYSIS
All values are expressed as the mean± SEM unless otherwise speci-
fied. Statistical significance was determined using non-parametric
Mann–Whitney t -test, unless otherwise specified. All statistical
analyses were carried out with the GraphPad Prism 4.0 Software.
In all experiments, differences were considered significant when p
was <0.05.
RESULTS
DEVELOPMENT OF METABOLIC DISORDERS IN AGED GHRLD MICE
We have shown previously that liver-specific deletion of GHR
result in lipid accumulation in hepatocytes and insulin resistance
(13). To investigate the long-term pathological impact of GH-
signaling deficiency, we examined the fasting blood glucose levels
of aged GHRLD mice (44–50 weeks old). Elevated levels of both
fasting blood glucose (Figure 1A, black arrow) and plasma insulin
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FIGURE 1 | Aged GHRLD mice developed glucose intolerance,
hyperlipidemia, and hepatic steatosis. (A) Intraperitoneal glucose
tolerance test of 44–50 weeks old GHRLD mice (n=13) and age-matched
controls (n=8). Arrow indicates the blood glucose levels of GHRLD mice
after overnight fasting (16 h). Data are presented as mean±SEM. *p<0.05;
**p<0.01. (B) Serum insulin levels in GHRLD (filled bars, n=13), or control
(open bars, n=6) mice. Sera were collected from either after overnight
fasting (0 min), 5- or 60-min after i.p. injection of a bolus of 2 g/kg of
d-glucose. Data are presented as mean±SEM. *p<0.05.
(C) Representative histological sections (H&E) of liver samples harvested
from 44 to 50 weeks old GHRLD (lower panels) and age-matched controls
mice (upper panels). Left panels, 5× objective lens magnification; right
panels, 20×. (D,E) Effect of liver-specific GHR deletion on lipoprotein
metabolism. Aliquots of plasma (250µl) pooled from individual mice in
GHRLD mice (n=6) and control mice (n=6) subjected to gel filtration
chromatography, followed by the determination of TG (D) and cholesterol
(E) concentrations in fractions. The peak fractions of 3–10, 14–23, and 40–50
in (D) represent VLDL, LDL, and HDL, respectively.
(Figure 1B) were observed. In addition, aged GHRLD mice exhib-
ited abnormalities in maintaining blood glucose homeostasis upon
intraperitoneal glucose challenge (IPGTT, Figure 1A), as well as
hyperinsulinemia (Figure 1B). Histological sections of liver tis-
sues harvested from GHRLD mice revealed severe steatosis, in line
with our previous findings on GHRLD mice of 8–16 weeks old
(Figure 1C).
GHRLD mice display elevated levels of plasma TG, increased
liver influx of free fatty acid, and markedly reduced VLDL–TG
liver output (13). To further understand the association of liver
GH signaling with lipid metabolism, we subjected plasma sam-
ples pooled from individual GHRLD mouse to gel filtration col-
umn chromatography and examined the TG composition in each
lipoprotein fractions. Striking differences of TG lipoprotein profile
were observed between GHRLD and control samples (Figure 1D):
GHRLD plasma samples exhibited marked increased levels of
VLDL–TG and LDL–TG, whereas HDL—TG levels were simi-
lar to controls. No significant difference of cholesterol levels was
observed between GHRLD and control mice (Figure 1E). Taken
together, these results suggested that GH signaling deficiency in
liver leads to hyperlipidemia and other features of the metabolic
syndrome.
PROTEOMIC ANALYSIS OF EFFECTS OF GH-SIGNALING DEFICIENCY IN
LIVER
To gain molecular insight of GH-signaling deficiency-mediated
hepatic steatosis, we harvested livers from 8- to 10-week male
GHRLD mice and age- and gender-matched controls and sub-
jected these samples to MALDI-based proteomic analysis. As
shown in Figure 2A, three protein spots/clusters whose expres-
sion levels were markedly altered (>2-fold) were identified
(Figure 2A, arrows). These were major urinary protein-1 (Mup1),
carboxylesterase 3A (Ces3a or Es31), and Selenium binding pro-
tein 2 (Selenbp 2). Mup1 is a secreted protein of the lipocalin fam-
ily, which forms complexes with pheromones in circulation and
excreted in urine to mediate chemical communication between
rodents. Recent studies have suggested additional roles of Mup1
in regulating metabolic homeostasis, by inhibiting the expression
of both gluconeogenic and lipogenic genes in the liver (22). While
the roles of Ces3a and Selenbp 2 in lipid metabolism remains
unknown, the TG hydrolase activity of other carboxylesterase fam-
ily members (e.g., Ces1) has been shown to regulate hepatic lipid
biosynthesis, secretion, deposition, and fatty acid oxidation in liver
(23, 24). To demonstrate that the observed differential protein
expression on the 2-D gel indeed reflected changes in protein
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FIGURE 2 | Proteomic analysis of effects of liver-specific GHR deletion.
(A) Proteins from 8- to 10-week old male GHRLD liver samples (n=4, left
panel) were extracted and compared to samples harvested from control
littermates (n=4, right panel) on 2-D electrophoresis (Isoelectric point pH
4–7). Arrows indicate proteins that were down-regulated in GHRLD liver,
which were further identified by mass spectrum. Red arrow, major urinary
protein-1 (Mup1); blue arrow, selenium binding protein 2 (Selenbp2); yellow
arrow, Caboxylesterase 3A (Cse3a or Es31). MW, molecular weight.
(B,C) Left panels, Western blot analyses of Cse3a (B) and Selenbp2
(C) expression levels; Right panels, semi-quantification of Western blot
results. (D) Levels of Mup1 in liver lysates of GHRLD (n=3) and control
(n=3) mice. ***p<0.001. (E) RT-qPCR analysis of mRNA expression of
genes identified by proteomics in GHRLD liver samples (n=4, gray bar),
normalized to controls (n=4, open bar).
translation levels, we performed Western blot analyses of Ces3a
and Selenbp 2 in liver samples of GHRLD mice (Figures 2B,C).
Consistent with results from the 2-D gel, marked decrease of
Selenbp 2 protein expression levels was observed (Figure 2C).
However, no significant change of Ces3a was detected (Figure 2C).
The discrepancy between 2-D gel and Western blot results might
be due to either changes in post-translational modifications (e.g.,
acetylation or phosphorylation), or cross reactivity of the primary
antibody to other isoforms of the Ces3 (e.g., Ces3b). The levels
of Mup1 expression in male GHRLD livers were also significantly
decreased, as demonstrated with ELISA (Figure 2D). RT-qPCR
analysis revealed significant decrease of mRNA transcript levels
of all three genes in male GHRLD liver (Figure 2E), suggest-
ing that GH-signaling regulates the expression of these genes at
transcription levels.
IMPACT OF GH-SIGNALING DEFICIENCY ON JAK/STAT PATHWAY
Liver-specific abrogation of both GHR and STAT5 results in
hepatic steatosis. To further understand the underlying molecular
mechanism, we performed RT-qPCR based Superarray analyses
to examine changes of the mRNA transcription of genes down-
stream of the STAT/JAK pathway. Among all the four genes that
were found to be altered >4-fold, Socs2, Socs3, and Egfr were
down-regulated, whereas Cyclin D1 (Ccnd1) was found to be up-
regulated (Figure 3A). Genes at the lower left corner (Mmp3,
A2m, and IL2a) with crossing points >25 (30, 29, and 28, respec-
tively) were excluded for further analysis as only background
levels of expression was detected. While acting as a key regula-
tor of cell-cycle in tissues with rapid renewal, Ccnd1 is expressed
in the liver at its quiescent stage, and has recently been impli-
cated in regulating the expression of gluconeogenic genes, via,
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FIGURE 3 | Superarray analysis of effects of GH-signaling deficiency
on the expression of genes related to the STAT/JAK signaling
pathway. (A) Total RNA samples from 8 to 10 weeks old male GHRLD
livers (n=6) were extracted and pooled, and were subjected to RT-qPCR
based Superarray analyses in triplicate. Levels of gene expression were
normalized to a composite group of house-keeping genes, and compared
to those of age-matched control samples (n=6). Shown is the scatter plot
comparing the levels of gene expression between GHRLD mice (y -axis)
and controls (x -axis). Among the 84 genes analyzed, only 4 highly
expressed genes (Ccnd1, Egfr, Socs2, and Socs3) exhibited >4-fold
alteration. The numbers represent the folds of changes of gene
expression, in comparison to controls. Red arrow and green arrows
indicate increase and decrease of gene expression in the GHRLD
samples, respectively. (B) RT-PCR analysis of Ccnd1 mRNA expression in
livers of 44–50 weeks old, male GHRLD (n=4) and control mice (n=4).
Neg, PCR reaction without cDNA input. (C) RT-qPCR analysis of Ccnd1
mRNA expression in GHRLD liver samples (n=4), in comparison with
controls (n=4). *p<0.05.
in part, inhibiting peroxisome proliferator-activated receptor γ
coactivator-1α (PGC1α) activity (25,26). Both SOCS2 and SOCS3,
members of suppressor of cytokine signaling (SOCS) family, are
negative regulators of the JAK/STAT signaling pathway. SOCS2 has
recently been implicated in regulating fat metabolism (27). While
the metabolic role of EGFR is largely unknown, EGFR was shown
as a critical regulator of hepatocyte proliferation for efficient liver
regeneration (28). These data suggest that GH-signaling deficiency
has broad impacts on various downstream events that are essential
for liver homeostasis.
IMPACT OF GH-SIGNALING DEFICIENCY ON THE EXPRESSION OF
FIBROTIC AND INFLAMMATORY GENES
Fat accumulation in the liver leads to increase of inflamma-
tion and fibrosis. To gain mechanistic insight into GH-signaling
deficiency-mediated NAFLD, we examined the mRNA transcrip-
tion of fibrotic genes (Figure 4A), as well as pro-inflammatory
cytokine genes (Figure 4B) by RT-qPCR analyses. As shown in
Figure 4A, the mRNA expression of both Col1A2 and Col3A1 were
significantly elevated in GHRLD livers. In consistence, expres-
sion of TGF-β, a key regulator of the fibrotic response, was
also increased (29). No difference of Col6A1 transcription was
observed between GHRLD liver samples and controls.
Transcription of CCL3 [Chemokine C–C motif ligand 3, also
known as macrophage inflammatory protein-1α (MIP-1α)], a
cytokine that is involved in the recruitment and activation of
neutrophils and other polymorphonuclear leukocytes in response
to acute inflammation, was up-regulated. TNFα expression is
also increased significantly, whereas levels of interleukin 1a and
1b (IL-1a and IL-1b) transcripts were not changed significantly
(Figure 4B). These results suggested that long-term fat accumu-
lation in GHRLD livers is associated with increased expression of
fibrotic and inflammatory genes.
PROGRESSION FROM NAFLD TO HEPATIC TUMOR FORMATION IN AGED
GHRLD MICE
We noticed that about 30–40% of livers in 55–70 weeks old
GHRLD mice displayed nodule like structures, whereas none was
observed in age-matched controls (Figures 5A,B). To validate that
the nodules observed were of neoplastic nature, we performed
RT-qPCR analysis of the levels of mRNA transcripts of Afp, the
gene that encodes the α-fetoprotein (AFP), which is abundantly
expressed in fetal liver, but silenced transcriptionally in adult. Ele-
vated levels of AFP in adult were used as a biomarker for the
development of liver tumors, such as hepatocellular carcinoma
(HCC) and hepatic adenoma. As shown in Figure 5C, the levels of
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FIGURE 4 | Effects of GHR deletion on fibrotic and inflammatory gene
expression. Liver tissues collected from 44 to 50 weeks old male GHRLD
mice (n=9) and age-matched controls (n=6) were used for the preparation
of total RNA. Hepatic mRNA levels of genes relevant to fibrosis (A) and
inflammation (B) were determined using real-time quantitative RT-PCR assay.
*p<0.05, **p<0.01, n.s. not significant.
FIGURE 5 | Development of hepatic tumors in 50–70 weeks old GHRLD
mice. (A) Summary of hepatic tumor development in aged GHRLD mice.
(B) Representative photographic images of livers of GHRLD (four on the
left) and control (one on the right) livers. Arrows indicate the tumors.
(C) RT-qPCR analysis of α-fetoprotein (AFP) mRNA expression, a marker for
hepatocelluar adenomas. *p<0.05.
Afp mRNA transcripts in GHRLD livers with nodules were signifi-
cantly higher than those of age-matched control livers, or GHRLD
livers with no nodule formation (Figure 5C).
Histological examination of GHRLD livers with nodules
showed that the nodule areas ranged from some macrovesicu-
lar steatosis with prominent steatosis and minor degree of nuclear
pleomorphism, to others with more prominent nuclear variation
including large cells with intranuclear inclusions (Figures 6A,B).
The nodules were not distinctly separated from the adjacent liver
by a capsule but showed distinct demarcation with some dilated
vessels at the edges of the nodules (Figures 6C,D). The majority
of the tumors represented adenomas similar to those of HNF1α-
mutated type, though no mutations or stains have been attempted
so far. In others, macrotrabecular arrangement was observed, indi-
cating the development of HCC (Figures 6E–G) (20). In one case,
the tumor had overwhelming lymphoid infiltrate and possibly rep-
resented an inflammatory adenoma (Figure 6H). Taken together,
these results suggest that the NAFLD in GHRLD mice can spon-
taneously develop to hepatic adenomas, which have the potential
to progress to HCC, even without any environmental insults.
To further demonstrate the pathological impact of hepatic
tumor formation on liver function, we examined the aspartate
aminotransferase (AST) and alanine transaminase (ALT) activi-
ties in sera GHRLD mice (Figure 7). Both AST and ALT activities
in GHRLD mice with hepatic tumors were significantly higher
than those of controls. In contrast, no elevation of serum AST and
ALT levels was observed in GHRLD mice with no obvious nodular
structure formation in livers.
DISCUSSION
Obesity and metabolic syndrome have become major medical
problems in developed countries (30) and affect children as well
as adults (31, 32). One of the consequences of the metabolic dis-
turbances in obesity is insulin resistance, resulting in excessive
deposition of fat within liver, known as steatosis or NAFLD. In
time, this NAFLD may progress to inflammatory changes with
fibrosis as evidence for steatohepatitis, cirrhosis, and development
of hepatocellular adenomas and carcinomas. While the molecular
etiology of NAFLD is not fully understood, it can be considered
as a hepatic manifestation of the metabolic syndrome. We and
others (13–16) have previously shown that deletion of GH sig-
naling in liver creates an insulin resistant state with compensatory
hyperinsulinemia, disturbed glucose tolerance, and clinical hepatic
steatosis from increased TG synthesis and decreased hepatic TG
export. These disturbances persist in aged mice as evident in
Figure 1. Rescue of GH signaling via adeno-viral restitution of
the GHR in liver (13), or STAT5 signaling in cells (16) may reverse
or prevent hepatic steatosis. Thus, deletion of GHR signaling in
liver recapitulates the metabolic syndrome associated with obesity,
which is itself a state of diminished GH secretion and hence dimin-
ished GH action on liver (33, 34). However, it should be pointed
out that while hepatic GH signaling is compromised under the
two conditions, the GH-deficient state is different: it is systemic in
obese subjects, but is restricted to hepatocytes in GHRLD mice.
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FIGURE 6 | Histological analysis (H&E) of hepatic adenomas in
50–70 weeks old GHRLD mice. Representative images of liver sections
(5µm) of control [(A), 200×] and GHRLD [(B,E,F), 200×; (C,G,H), 50×;
(D), 400×] mice. Arrows in (B) show the abnormal nuclear variations.
While dotted lines in (C,E) show the boundaries between the tumor
region and the adjacent hepatic steatotic region. Yellows arrows in
(C) indicate the dilated blood vessels at the edges of the nodular
structure. (E) shows typical images of benign hepatic adenoma, similar
to HNF1α mutated type. (F,G) show regions of atypical hepatic
adenomas with macrotrabecular arrangement, resembling areas of HCC.
Dotted line in (H) shows the massive infiltration of immune cells in one
case of hepatic adenoma.
In addition, GHRLD mice display elevated levels of circulating
GH, which might have direct or indirect effects on lipid metabo-
lism and insulin sensitivity in peripheral tissues (e.g., muscle and
fat). Nevertheless, association between lower serum GH levels and
NAFLD has been demonstrated in a recent cross sectional study
(35); the GHRLD model could be used to unravel the contri-
bution of compromised hepatic GH signaling in NAFLD and its
progression.
Consistent with reports of progression in human obesity-
associated NAFLD to fibrosis, steatohepatitis, and adenoma-
carcinoma formation, we show in this study that evidence of
inflammation and fibrosis is present in the livers of mice with
liver-specific deletion of GH signaling. In some of these mice, the
changes in livers progress to adenoma formation. Markers of fibro-
sis (Figure 4A) and inflammation (Figures 4B and 7) are markedly
elevated. Our data suggest that abrogation of GH signaling in liver
results in a metabolic profile consistent with that observed in the
human metabolic syndrome, hepatic steatosis (NAFLD), which
may progress to hepatic fibrosis, inflammation (NASH), and liver
dysfunction (increased ALT/AST) eventually leading to hepatic
adenoma formation. This sequence of events is similar to that of
human obesity-related progression of insulin resistance, impaired
glucose tolerance, hyperlipidemia, and liver abnormalities that
include NAFLD, NASH, and rarely hepatic adenoma formation.
Thus, our model may serve to evaluate the molecular mechanisms
that define these transitions, determine which factors are respon-
sible for progression to adenoma formation, and identify potential
targets for treatment.
Our results are in line with previous findings on the roles of
STAT5 in maintaining liver homeostasis. Similar to GHRLD, loss of
STAT5 in liver tissue results in severe steatosis, progression to fibro-
sis (17), and eventual development of HCC at 17 months of age
(36). The hepatic tumorigenesis can be accelerated with either car-
cinogen carbon tetrachloride (CCl4) treatment (37) or concurrent
abrogation of the glucocorticoid (GC)-responsive glucocorticoid
FIGURE 7 | Elevation of AST and ALT levels in sera of 50–70 weeks old
GHRLD mice. Serum samples of GHRLD mice with tumors (filled black
bars, n=5), GHRLD mice without tumors (filled gray bars, n=6) and
age-matched control mice (open bars, n=5) were subjected to analyses of
AST (left panel) and ALT (right panel) levels. *p<0.05, **p<0.01. No
significant difference was observed between controls and GHRLD mice
without hepatic tumor formation.
receptor (GR), another mediator of GH signaling in liver (38).
Interestingly,35% of STAT5/GR double-deficient mice display dys-
plastic nodules on livers and more than half of which progress to
HCC at 12 months of age, in striking similarity to GHRLD males.
Thus, impairment of the GH-STAT5/GR signaling cascade leads to
severe defects in lipid homeostasis and spontaneous development
of HCC.
Numerous factors could contribute to the tumorigenesis in
aged GHRLD mice. Ccnd1, a member of the cyclin family, which
is involved in cell-cycle G1/S transition and interactions with
tumor suppressors, is overexpressed (Figure 3). Over expression
of this gene may alter cell-cycle progression, has been observed
in various tumors, and possibly contributed to tumor forma-
tion in our GHRLD mice (39). Similar to STAT5-deficient livers,
hepatic transcription of tumor SOCS2 was also found decreased
in GHRLD mice (40). Recently, Yu et al. showed recently that GH,
Frontiers in Endocrinology | Pediatric Endocrinology December 2014 | Volume 5 | Article 218 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fan et al. GHRLD mice develop liver tumor
through STAT5, regulates the expression of key proapoptotic pro-
teins (PUMA and BIM) in liver, further highlighting the tumor
suppressive function of the GH-STAT5 axis (36). Moreover, more
evidence has accumulated implicating that hyperinsulinema and
insulin-resistance, both present in GHRLD mice, could lead to
deregulation of insulin receptor (IR), especially its IR-A isoform,
in malignant cells and promote tumor progression (41, 42).
It has been suggested that inactivating mutations in HNF1α
and activating mutations in β-catenin within the hepatocellular
adenomas serve to classify clinical and prognostic factors such as
progression to carcinoma as proposed for β catenin mutations
(43–45). Obesity appears to amplify inflammation and other fac-
tors that promote tumorigenesis (46, 47). In our mouse model, it is
not clear why only 30–40% of the animals develop the adenomas,
and what, if any, molecular markers distinguish those animals that
do from those that do not develop adenomas. These aspects require
further research and could offer new insights into the pathophys-
iology of hepatic dysfunction in obesity, and the prevention of
progression from NAFLD to tumor formation.
The world-wide epidemic of obesity has resulted in an increase
of NAFLD in adults and children (4, 30–32). Because obesity is
a state of diminished spontaneous and stimulated GH secretion
(33, 34), it has been proposed that NAFLD in obesity has similar
mechanisms to that observed in the animal models of decreased
GH signaling in liver (13, 16). Hence, appropriately structured
trials of treatment with GH have been proposed as a means of
avoiding or diminishing the risk for NAFLD in obesity (16). If
effective, such treatment would also diminish the risk of hepatic
adenoma formation.
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